[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"gastric-type-adenocarcinoma-gas-with-stk11-mutation\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:gastric-type-adenocarcinoma-gas-with-stk11-mutation":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":5},"100525686","phase-2-a-study-of-wx390-combined-with-toripalimab-in-patients-with-advanced-gastric-type-endocervical-adenocarcinoma-with-stk11-mutations-100525686",false,"NCT06124963","A Study of WX390 Combined With Toripalimab in Patients With Advanced Gastric-type Endocervical Adenocarcinoma With STK11 Mutations","A Phase II Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of WX390 Combined With Toripalimab in Patients With Advanced Gastric-type Endocervical Adenocarcinoma With STK11 Mutations","Inclusion Criteria:\n\n* ≥18 years of age\n* Histological or cytological confirmed advanced Gastric-type Endocervical Adenocarcinoma.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-1\n* Life expectancy of more than 3 months\n* At least one measurable lesion according to RECIST 1.1\n* Adequate organic function\n* Signed and dated informed consent\n\nExclusion Criteria:\n\n* Anti-cancer therapy within 30 days prior to the initiation of investigational treatment\n* Major surgery within 30 days prior to the initiation of study treatment\n* Received corticosteroids treatment or other immunodepressant within 2 weeks before the first dose of study treatment\n* Toxicity from a previous anti-tumor treatment that does not return to Grade 0 or 1 (except for alopecia)\n* Patients who are suffering active interstitial lung disease\n* Evidence of ongoing or active serious infection\n* History of human immunodeficiency virus (HIV) infection or active hepatitis B or C infection\n* Inability to take medication orally\n* Abuse of alcohol or drugs\n* People with cognitive and psychological abnormality or with low compliance\n* Pregnant or lactating women","FEMALE","18 Years",{"count":19,"type":20},20,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","The goal of this clinical trial is to evaluate the safety and preliminary efficacy of WX390 combined with Toripalimab in patients with advanced Gastric-type Endocervical Adenocarcinoma with STK11 mutations. The main questions it aims to answer are:\n\n* Pharmacokinetic (PK) characteristics of WX390 combined with Toripalimab treatment.\n* Safety and preliminary in combined therapy. Participants will be treated with WX390 orally and Toripalimab intravenously, and follow the efficacy and safety evaluation according to the protocol.",[26],"Gastric Type Adenocarcinoma (GAS) With STK11 Mutation","RECRUITING","2024-12-09",{"date":30,"type":31},"2024-12-10","ACTUAL",{"date":33,"type":31},"2023-08-25",{"date":35,"type":20},"2026-12-09",{"name":37,"class":38},"Shanghai Jiatan Pharmatech Co., Ltd","INDUSTRY"]